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The first phase III study of bevaci-
zumab in combination with chemotherapy
in patients with nonsquamous non-small
cell lung cancer (E4599) was conducted in
the United States, and both progression-
free survival (PFS) and overall survival
(OS) were significantly improved in the
bevacizumab arm1: however, in the sec-
ond phase III study (AVAiL) conducted in
the European Union, there was no signif-
icant difference in OS.2
When clinicians make a treatment
decision, there are three important points
to be considered: whether it prolongs OS,
whether it improves patients’ quality of
life, and how much it costs. Regarding
bevacizumab, the cost is high, and its
toxicity could compromise quality of life
and sometimes lead to serious conditions,
such as pulmonary hemorrhage and
thromboembolism. Therefore, OS im-
provement is necessary by using bevaci-
zumab; however, only one phase III
study has shown a survival advantage of
bevacizumab as mentioned above. Con-
sequently, skeptical oncologists do not
use bevacizumab for non-small cell lung
cancer patients even if they are free from
contraindications.
Table 1 summarizes the results of
three randomized studies of bevacizumab,
E4599,1 AVAiL,2 and a Japanese phase II
study (JO19907).3 As shown from the im-
proved response rate and PFS, bevaci-
zumab has reproducibly demonstrated
a strong antitumor effect throughout the
studies; however, only the E4599 study
demonstrated improved OS. How could we
use this potent drug appropriately?
Broglio and Berry4 addressed the
importance of survival postprogression
(SPP) and pointed out that lack of statis-
tical significance in OS does not necessar-
ily imply lack of improvement in OS,
especially when SPP is longer than 12
months. Despite the recent development
of efficient second- or third-line chemo-
therapy, SPP longer than 12 months is not
so common, except in patients with acti-
vating epidermal growth factor receptor
(EGFR) mutations. It seems quite reason-
able to assume that more than 30% of
included patients (East-Asian, nonsqua-
mous) had EGFR mutations and would
have received EGFR-tyrosine kinase in-
hibitor when disease progressed in each
arm, and the marked improvement of OS
in those patients might have negated the
significant difference in PFS in the
JO19907 study.
Collectively, bevacizumab in com-
bination with chemotherapy may be more
recommendable for patients with wild-
type EGFR than patients with EGFR mu-
tations in the current situation. As for
patients with EGFR mutants, the recently
published BeTa study,5 a randomized
phase III study comparing second-line er-
lotinib with or without bevacizumab, may
be useful. In this study, PFS doubled (3.4
versus 1.7 months, hazard ratio [HR]:
0.62), but OS was almost identical (9.3
versus 9.2 months, HR: 0.97). Interest-
ingly, the improvement of OS was more
prominent in EGFR mutants (HR: 0.44)
than EGFR wild-type (HR: 1.11) in sub-
group analysis. As the authors mentioned,
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TABLE 1. Randomized Studies of First-Line Bevacizumab in Combination with
Chemotherapy in NSCLC
E4599 AVAiL JO19907
Bev — 15 mg — 7.5 mg 15 mg — 15 mg
N 444 434 347 345 351 59 121
RR (%) 15 35 20 34 30 31 61
PFS (mo) 4.5 6.2 HR 6.1 6.7 6.5 HR 5.9 6.3 HR
0.66 0.75 (7.5 mg) 0.61
0.82 (15 mg)
OS (mo) 10.3 12.3 HR 13.7 14.1 14.5 HR 23.4 22.8 HR
0.79 0.94 (7.5 mg) 0.99
0.97 (15 mg)
NSCLC, non-small cell lung cancer; RR, response rate; PFS, progression-free survival; OS, overall survival; HR,
hazard ratio.
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 Letters to the Editor
Copyright © 2011 by the International Association for the Study of Lung Cancer 2145
this result should be interpreted with cau-
tion because only 30 patients in the study
had EGFR-mutated tumors and the 95%
confidence intervals for the HRs were
wide (upper limit 1) and overlapping;
however taking account of this promising
data, bevacizumab combined with EGFR-
tyrosine kinase inhibitor is attractive for
patients with EGFR mutations and ran-
domized studies are warranted.
Young Hak Kim, MD, PhD
Michiaki Mishima, MD, PhD
Department of Respiratory Medicine
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The place of extra pleural pneu-
monectomy (EPP) in the treatment of
N0-1 epithelioïd mesothelioma with cu-
rative intent is still debatable. Posto-
perative hemithoracic radiotherapy has
been recommended, since the publica-
tion of Rusch in 2001. Nevertheless,
peritoneal or contralateral pleural recur-
rences are frequent in the literature.
We read with interest the article
by Rice et al.1 in the August issue of
the journal that the recommendations
of the International Association for the
Study of Lung Cancer and the Interna-
tional Mesothelioma Interest Group
concerning EPP state that “in cases
where the pericardium and/or dia-
phragm are not involved by tumor,
these structures may be left intact.” In
our consecutive series of 15 patients,
we preserved the pericardium and the
diaphragm to avoid peritoneal or
pericardial seeding of the tumor.2
Polyglactin woven mesh was used to
reinforce the denervated diaphragm to
lower it, open the pleural sac, and
facilitate radiotherapy. There were no
postoperative deaths. Preservation of
the diaphragm and pericardium seems
to facilitate the postoperative course
without increase of recurrences in
these areas.
For the last 4 years, we have rou-
tinely performed a laparoscopy, a con-
tralateral thoracoscopy, and a mediasti-
noscopy during the same anesthesia, 1
week before EPP. During this period, 10
laparoscopies were carried out and 3 peri-
toneal invasions were detected which ex-
cluded resection for those patients.
As stated by Chi et al.3 in the June
issue of the journal, local control re-
mains poor despite conventional adju-
vant hemithoracic radiotherapy. This
can be improved by the delivery of ad-
juvant intensity-modulated radiotherapy
and especially helical tomotherapy
which we adopted for the last five pa-
tients in our series.4
In our opinion, this current strat-
egy should minimize postoperative mor-
tality, local recurrences, and peritoneal
and contralateral pleural seeding.
We noted the disappointing results
following EPP in the small MARS fea-
sibility study,5 but in the EPP arm, 5
patients had no surgery, it was com-
pleted satisfactorily in only 16 of 24
patients, 4 patients died perioperatively,
and only 8 received conventional radio-
therapy, and it is too early to draw con-
clusions from this study.
Pierre Bonnette, MD
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